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Summary
Background WHO recommends combinations of an artemisinin derivative plus an antimalarial drug of longer half-life 
as treatment options for uncomplicated Plasmodium falciparum infection. In Africa, artemether–lumefantrine is the 
most widely used artemisinin-based combination therapy, whereas artesunate–meﬂ oquine is used infrequently 
because of a perceived poor tolerance to meﬂ oquine. WHO recommends reconsideration of the use of artesunate–
meﬂ oquine in Africa. We compared the eﬃ  cacy and safety of ﬁ xed-dose artesunate–meﬂ oquine with that of artemether–
lumefantrine for treatment of children younger than 5 years with uncomplicated P falciparum malaria.
Methods We did this multicentre, phase 4, open-label, non-inferiority trial in Burkina Faso, Kenya, and Tanzania. 
Children aged 6–59 months with uncomplicated malaria were randomly assigned (1:1), via a computer-generated 
randomisation list, to receive 3 days’ treatment with either one or two artesunate–meﬂ oquine tablets (25 mg artesunate 
and 55 mg meﬂ oquine) once a day or one or two artemether–lumefantrine tablets (20 mg artemether and 120 mg 
lumefantrine) twice a day. Parasitological assessments were done independently by two microscopists who were 
blinded to treatment allocation. The primary outcome was the PCR-corrected rate of adequate clinical and parasitological 
response (ACPR) at day 63 in the per-protocol population. Non-inferiority was shown if the lower limit of the 95% CI 
for the diﬀ erence between groups was greater than –5%. Early vomiting was monitored and neuropsychiatric status 
assessed regularly during follow-up. This study is registered with ISRCTN, number ISRCTN17472707, and the 
Pan African Clinical Trials Registry, number PACTR201202000278282.
Findings 945 children were enrolled and randomised, 473 to artesunate–meﬂ oquine and 472 to artemether–
lumefantrine. The per-protocol population consisted of 407 children in each group. The PCR-corrected ACPR rate at 
day 63 was 90·9% (370 patients) in the artesunate–meﬂ oquine group and 89·7% (365 patients) in the artemether–
lumefantrine group (treatment diﬀ erence 1·23%, 95% CI –2·84% to 5·29%). At 72 h after the start of treatment, no 
child had detectable parasitaemia and less than 6% had fever, with a similar number in each group (21 in the 
artesunate–meﬂ oquine group vs 24 in the artemether–lumefantrine group). The safety proﬁ les of artesunate–
meﬂ oquine and artemether–lumefantrine were similar, with low rates of early vomiting (71 [15·3%] of 463 patients in 
the artesunate–meﬂ oquine group vs 79 [16·8%] of 471 patients in the artemether–lumefantrine group in any of the 
three dosing days), few neurological adverse events (ten [2·1%] of 468 vs ﬁ ve [1·1%] of 465), and no detectable 
psychiatric adverse events.
Interpretation Artesunate–meﬂ oquine is eﬀ ective and safe, and an important treatment option, for children younger 
than 5 years with uncomplicated P falciparum malaria in Africa.
Funding Agence Française de Développement, France; Department for International Development, UK; Dutch 
Ministry of Foreign Aﬀ airs, Netherlands; European and Developing Countries Clinical Trials Partnership; Fondation 
Arpe, Switzerland; Médecins Sans Frontières; Swiss Agency for Development and Cooperation, Switzerland.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.
Introduction
Since 2000, there has been substantial progress in the 
worldwide eﬀ ort to control, and in some regions 
eliminate, malaria.1 However, the disease still caused an 
estimated 438 000 deaths worldwide in 2015, mostly in 
Africa (90%) and in children younger than 5 years 
(70%).1,2 The widespread deployment of artemisinin-
based combination therapies (ACTs) for treating malaria 
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is recognised as one key public health initiative for 
reducing malaria morbidity and mortality. Five ACTs are 
currently recommended by WHO for the treatment of 
uncomplicated Plasmodium falciparum infection,3 the 
predominant cause of malaria in Africa and, when 
untreated, the most deadly form of malaria worldwide.2
Antimalarial drugs are used in combinations to prevent 
or delay the development of drug resistance and are now 
recommended in most malaria-endemic countries.4 
Monotherapy with artemisinin or its derivatives is now 
strongly discouraged,3 especially after the emergence of 
artemisinin resistance in some regions.5 Deployment of 
multiple ACTs is regarded to be a further means to 
reduce development of drug resistance.6 Several eﬀ ective 
ACTs are now available, many as ﬁ xed-dose formulations,3 
which oﬀ er improved patient adherence. Artemether–
lumefantrine was the ﬁ rst ﬁ xed-dose ACT to become 
available and is currently the most extensively used ACT.2
The Drugs for Neglected Diseases initiative (DNDi), in 
partnership with the TDR (the Special Programme for 
Research and Training in Tropical Diseases) consortium, 
has collaborated with industry and academia for the 
development of two ﬁ xed-dose ACTs.7 This partnership 
formed the FACT (Fixed-dose Artesunate-based Comb-
ination Therapy) project consortium, which is a model 
needs-driven initiative aiming to increase availability and 
reliable supply of ﬁ xed-dose ACTs of required quality.
One of the ﬁ ve WHO-recommended ACTs is artesunate 
with meﬂ oquine. Available in loose or ﬁ xed-dose comb-
ination, artesunate–meﬂ oquine showed high eﬃ  cacy in 
treating uncomplicated P falciparum malaria8–10 and has 
been used extensively over 20 years, mostly in Asia and 
Latin America.11 This combination is less commonly 
used in Africa, because of the availability of other 
aﬀ ordable and already registered ACTs.3 Reports of 
meﬂ oquine resistance in Asia,12 shortly after the drug’s 
introduction as monotherapy in the 1990s, had a negative 
eﬀ ect on the introduction of artesunate–meﬂ oquine in 
Africa. Furthermore, excessive vomiting associated with 
meﬂ oquine seems the main reason for the restricted use 
of artesunate–meﬂ oquine in African children. Early 
vomiting, shortly after treatment, is a reported cause of 
treatment failure in children.13 However, WHO has 
recommended that artesunate–meﬂ oquine be recon-
sidered for treatment of uncomplicated malaria in Africa, 
particularly highlighting the paucity of data for this 
combination in children younger than 5 years.3
A ﬁ xed-dose artesunate–meﬂ oquine (containing 100 mg 
artesunate and 220 mg meﬂ oquine hydrochloride) was, 
therefore, developed in Brazil by Farmanguinhos, through 
Research in context
Evidence before this study
A systematic search of PubMed was done on Nov 25, 2014, 
without date or language restrictions, with the terms 
“artesunate” and “meﬂ oquine” and “malaria, falciparum” 
and “ACPR” and “non-inferiority”. We found no randomised 
trials that tested the eﬃ  cacy and safety of ﬁ xed-dose 
artesunate–meﬂ oquine in young children in Africa according 
to the WHO recommendations.
WHO recommends “adequate clinical and parasitological 
response (ACPR)” (corrected for possible re-infections and a 
per-protocol analysis) as the primary outcome and a 
non-inferiority trial design with a follow-up of adequate 
duration, which is 63 days to allow for the prolonged clearance 
rate of meﬂ oquine. We found two trials (Smithuis et al, 2010; 
Ashley et al, 2006) of the ﬁ xed-dose artesunate–meﬂ oquine 
tablet with ACPR at day 63 of follow-up as the primary 
outcome. These studies were done in Asia in populations of 
mixed age. Four trials (Faye et al, 2007; Agomo et al, 2008; 
Sagara et al, 2008; Bhatt et al, 2006) of ﬁ xed-dose 
artesunate–meﬂ oquine were done in Africa in populations of 
mixed age but with ACPR at 28 days as the primary outcome.
Added value of this study
As far as we are aware, our trial is the ﬁ rst to be reported on a 
ﬁ xed-dose artesunate–meﬂ oquine formulation and done in young 
African patients with a trial design that fully complies with WHO 
guidelines. It is the largest randomised, controlled trial providing 
eﬃ  cacy and safety data for artesunate–meﬂ oquine in children in 
Africa. Our ﬁ ndings showed that artesunate–meﬂ oquine is 
non-inferior to artemether–lumefantrine for the primary endpoint 
of PCR-corrected ACPR rate at day 63. We also found that the 
two treatments had similarly good safety proﬁ les, with low rates 
of early vomiting and few recorded neurological adverse events. 
Our eﬃ  cacy and safety data are consistent with the ﬁ ndings of 
large trials (Smithuis et al, 2010; Ashley et al, 2006) of the same 
ﬁ xed-dose tablet, which were done in Asia in mixed-aged patients 
with uncomplicated malaria. Additionally, we obtained evidence 
that artesunate–meﬂ oquine might delay re-infection for longer 
than artemether–lumefantrine does, which might be explained by 
the much slower rate of clearance of meﬂ oquine compared with 
lumefantrine.
Implications of all the available evidence
Artesunate–meﬂ oquine is one of ﬁ ve artemisinin-based 
combination therapies (ACTs) that are currently recommended 
by WHO as antimalarial treatments. However, this 
combination was not registered in Africa at the time of the 
start of the trial. WHO recommends deployment of multiple 
ACTs to reduce the risk of the development of drug resistance. 
Our data suggest that ﬁ xed-dose artesunate–meﬂ oquine is 
safe and eﬀ ective in treating young children with 
uncomplicated malaria in Africa and is as eﬀ ective as 
artemether–lumefantrine. These ﬁ ndings should have 
important implications for health policy in Africa, where 
malaria remains a major public health problem, particularly 
in young children. 
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the FACT consortium, and registered there in 2008. A 
pivotal study in Thailand, involving 500 patients with 
uncomplicated malaria, including children (aged 
<15 years),14 showed this ﬁ xed-dose combination to be 
better tolerated, with a lower incidence of vomiting, than 
equivalent loose tablet combinations. A randomised 
comparative trial in Burma showed that this ﬁ xed-dose 
artesunate–meﬂ oquine had, compared with other ACTs 
(loose artesunate–meﬂ oquine, artemether–lumefantrine, 
artesunate–amodiaquine, dihydroartemisinin–piperaquine), 
the highest cure rate, the lowest rate of gametocyte 
carriage, and the most eﬀ ective suppression of Plasmodium 
vivax malaria,9 and a large phase 4 trial (23 845 patients) in 
Brazil conﬁ rmed its eﬀ ectiveness as a treatment of 
uncomplicated P falciparum infection.8
We did a randomised, multicentre, phase 4 trial with 
the aim of obtaining the most deﬁ nitive evidence so far 
on the eﬃ  cacy and safety of ﬁ xed-dose artesunate–
meﬂ oquine in children younger than 5 years with 
uncomplicated P falciparum malaria in Africa. The trial 
design was based on WHO guidelines15 and compared the 
eﬃ  cacy and safety of ﬁ xed-dose artesunate–meﬂ oquine 
with that of ﬁ xed-dose dispersible artemether–
lumefantrine. Because of the long half-life of meﬂ oquine, 
there was a prolonged follow-up (63 days), with an 
extensive safety assessment.
Methods
Study design and participants
This phase 4, multicentre, open-label, randomised, 
non-inferiority trial was done in six medical research 
centres across three African countries: Kilosa, Bagamoyo, 
and Korogwe (Tanzania); Balonghin and Banfora 
(Burkina Faso); and Ahero-Kisumu (Kenya).
Children were eligible for inclusion if they were aged 
6–59 months, had an axillary temperature of 37·5°C or 
more, and had uncomplicated P falciparum monoinfection 
(2000–200 000 asexual parasites per μL). Exclusion criteria 
were signs and symptoms of severe or complicated 
malaria; bodyweight less than 5 kg; inability to tolerate 
oral medication; mixed Plasmodium species infection; 
fever caused by non-malarial disease; hypersensitivity 
to meﬂ oquine, quinine, quinidine, artesunate, or other 
artemisinins; antimalarial treatment within the previous 
2 weeks (4 weeks for meﬂ oquine or piperaquine); and 
participation in a clinical intervention trial within the 
previous 3 months. Informed consent was obtained from 
the child’s parent or legal guardian.
The trial was done in accordance with the Declaration 
of Helsinki and international and local national laws 
for protecting human rights and welfare. Ethical and 
regulatory approvals were obtained separately by each 
study centre: in Burkina Faso from the Ethics Review 
Committee of the Ministry of Health; in Tanzania from 
the National Health Research Ethics Review Committee 
and from the Tanzania Food and Drugs Authority; and in 
Kenya from the KEMRI Institutional Review Board and 
from the Kenyan Expert Committee on Clinical Trials/
Pharmacy and Poisons Board.
An independent data safety monitoring committee was 
established to advise the sponsor if it was of the opinion 
that the ongoing trial had provided evidence that all or a 
speciﬁ c subgroup(s) could either beneﬁ t from or be 
contraindicated for artesunate–meﬂ oquine, on the basis 
of diﬀ erence in the primary endpoint; evidence of 
drug-related toxic eﬀ ects that outweighs the beneﬁ ts of 
artesunate–meﬂ oquine; or evidence that might reasonably 
be expected to inﬂ uence patient management by clinicians 
who have become aware of any of the main trial results. 
The basis of any decision of the data safety monitoring 
committee was the content of any serious adverse event 
reports, all of which were received from the investigators 
without delay, and reviews of the study database done at 
regular intervals during the study.
Randomisation and masking
Eligible children were randomly assigned (1:1) to receive 
artesunate–meﬂ oquine or artemether–lumefantrine. 
Treatment allocation was made using a computer-
generated randomisation list and, for each patient, the 
allocated treatment was transmitted in a sealed envelope 
to the nurse or physician administering the treatment. 
This study was open label; however, laboratory 
technicians who did the parasitological assessments 
were masked to treatment allocation.
Procedures
The paediatric ﬁ xed-dose artesunate–meﬂ oquine tablet 
(25 mg artesunate and 55 mg meﬂ oquine hydrochloride, 
containing no ﬂ avouring [Farmanguinhos, Rio de Janeiro, 
Brazil]), is a round, smooth, biconvex, blue-coated tablet of 
6·0 mm diameter; it was given once a day for 3 days, 
either as one tablet (for children aged 6–11 months) or two 
tablets (for children aged 12–59 months). The ﬁ xed-dose 
artemether–lumefantrine dispersible tablet (20 mg 
artemether and 120 mg lumefantrine, containing ﬂ avour-
ing [Novartis Pharmaceuticals, Basel, Switzerland]), was 
dispersed in 200 mL milk (or breastmilk); it was given 
twice a day for 3 days, either as one tablet (for bodyweight 
≥5 kg to <15 kg) or two tablets (for bodyweight ≥15 kg to 
<25 kg). Treatment was supervised and children observed 
for 60 min after treatment for possible vomiting. Test drug 
was readministered if vomiting occurred within 60 min. 
Patients with persistent vomiting and requiring more 
than a single repeat dose were excluded from the study 
and referred for further clinical management.
Children were followed up to day 63 after the start of 
treatment or to the ﬁ rst recurrence (ﬁ rst follow-up 
period). Patients with parasitaemia during follow-up were 
then switched to the alternative test treatment (except in 
Burkina Faso, where quinine was used for parasitaemia 
occurring within 28 days of the start of initial treatment, 
according to a national recom mendation) and another 
63 days of follow-up was started (second follow-up 
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period), to collect eﬃ  cacy and safety data, because 
artesunate–meﬂ oquine was not a registered medicine in 
the participating countries.
Clinical signs, including neuropsychological obser-
vations, were assessed and recorded before and during 
the ﬁ rst 3 days post treatment, and on follow-up visits on 
days 7, 14, 21, 28, 35, 42, 49, 56, and 63 (of ﬁ rst follow-up) 
and on days 7, 28, and 63 post recurrence (of second 
follow-up), and whenever required. Adverse events and 
concomitant drug treatment were systematically recorded 
at each visit, with haematological and biochemical 
analyses done on samples taken on days 0, 7, 28, and 63, 
and whenever clinically required. Investigators recorded 
whether results of patient examinations and sample 
analyses were normal or abnormal (with detailed 
description of any abnormalities). Concomitant drug 
treatment was recorded, with paracetamol allowed for 
fever. Intake of any drug with antimalarial properties led 
to study withdrawal.
Parasitological assessments (thick and thin blood 
ﬁ lms) were done independently by two microscopists 
(blinded to treatment allocation) at least once every 24 h 
or until parasite clearance (deﬁ ned as two consecutive 
negative readings 8–24 h apart), and then, on days 7, 14, 
21, 28, 35, 42, 49, 56, and 63, and whenever required. 
Parasite density was expressed as number of asexual 
parasites per μL blood, calculated from a count relative to 
200 or 300 counted white blood cells and the blood cell 
density; a negative count was 1000 white blood cells 
counted without detecting any asexual parasites.
Recrudescence and re-infection were diﬀ erentiated by 
characterising malaria strains of initial infection and of 
recurrence, using internationally prescribed procedures16 
for PCR genotypic analysis of extensively diverse genes 
(msp1, msp2, glurp) in blood collected immediately before 
treatment (baseline) and on day of recurrence.
In the ﬁ rst amendment of the original study protocol, 
the study was extended to include sites in Kenya 
and Burkina Faso, the sampling sequence of the 
pharmacokinetic part of the study was increased to be 
consistent with the product’s half-life, and an additional 
sampling for PCR analysis was included at day 7, in 
accordance with WHO recommendations. The second 
amendment included addition of the second 63-day 
follow-up. In the third amendment, the major change 
was the addition of new sites (Korogwe and Bagamoyo) 
in Tanzania, to reach the required number of patients.
Figure 1: Trial proﬁ le
The intention-to-treat population consisted of all randomly allocated patients 
who received at least one dose of study drug. The per-protocol population 
consisted of all patients without a major protocol deviation, who were fully 
treatment compliant (deﬁ ned as ≥80% and <120% intake of study drug), who 
had a primary endpoint at day 63, and who did not withdraw from study 
treatment (except for those who withdrew because of adverse events or an 
absence of eﬃ  cacy). The safety analyses included all randomly allocated patients 
who took at least one dose of study drug and had at least one exploitable safety 
measure. *Some patients had more than one protocol violation. †Reason for 
withdrawal was other than recurrences or adverse event during follow-up. 
473 assigned to artesunate–
 mefloquine (3-day treatment 
 in hospital)
1 did not take study drug
472 assigned to artemether–
 lumefantrine (3-day treatment 
 in hospital)
62 completed second follow-up 
 period (assessments on days 7, 28, 
 and 63)
49 completed second follow-up  
 period (assessments on days 7, 28, 
 and 63)
204 completed first 63-day follow-up 
 period (assessments on days 7, 
 14, 21, 28, 35, 42, 49, 56, and 63)
If recurrent parasitaemia, switch to the 
alternative treatment, but, in Burkina Faso and 
if before day 28, switch to quinine
945 randomly assigned to treatment
 390 Banfora and Balonghin, Burkina Faso
 113 Korogwe, Tanzania
 55 Bagamoyo, Tanzania
 40 Kilosa, Tanzania
 347 Kisuma, Kenya
2339 patients screened for eligibility 1394 ineligible
 555 low or no parasitaemia
 93 severe malaria or high 
 parasitaemia
 49 mixed infection
 298 other disease present
 149 withdrew consent 
 before randomisation
 173 antimalarial treatment 
 within last 2 weeks
 77 other
202 completed first 63-day follow-up 
 period (assessments on days 7, 14, 
 21, 28, 35, 42, 49, 56, and 63)
472 (99·8%) included in intention-
 to-treat population
472 (100%) included in intention-
 to-treat population
407 (86%) included in per-protocol 
 population
407 (86%) included in per-protocol
 population
65 excluded from per-protocol
 analysis
 31 major protocol violation*
 2 non-compliant with 
 eligibility criteria
 7 last blood smear not 
 performed
 17 treatment compliance of 
 <80% or >120%
 5 PCR not done or missing
 5 took forbidden 
 medication
 3 took wrong dose or failed 
 to follow protocol
 14 discontinued study drug
 34 withdrew†
 7 parent's decision
 1 investigator's decision
 22 lost to follow-up
 2 took antibiotics with 
 antimalarial activity
 2 took other antimalarial 
 drug
65 excluded from per-protocol
 analysis
 22 major protocol violation*
 11 last blood smear not 
 performed
 10 treatment compliance 
 <80% or >120%
 5 PCR not done or missing
 1 took forbidden 
 medication
 1 randomisation error
 11 study drug discontinued
 43 withdrew†
 16 parent's decision
 22 lost to follow-up
 2 took antibiotics with 
 antimalarial activity
 3 took other antimalarial 
 drug
468 (98·9%) included in safety population 465 (98·5%) included in safety population
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Outcomes
Treatment outcomes (classiﬁ ed using standard deﬁ nitions 
and adjusted to the 63 days of follow-up) were adequate 
clinical and parasitological response (ACPR), early 
treatment failure, late parasitological failure, and late 
clinical failure. At intervals after the start of treatment, we 
calculated the gametocyte carriage (percentage of patients 
with gametocytes) and the parasite reduction ratio 
(baseline parasite count/parasite count at the speciﬁ c 
interval).
The primary eﬃ  cacy endpoint was PCR-corrected ACPR 
rate at day 63 (in the per-protocol population). The 
secondary eﬃ  cacy endpoints were non-PCR-corrected 
ACPR rate at day 63; Kaplan-Meier analysis of number of 
patients with ACPR after PCR correction; proportion of 
patients with early treatment failure, late treatment failure, 
and late parasitological failure; proportion of patients 
with recrudescence or re-infection; PCR-corrected and 
non-PCR-corrected ACPR rates on days 28 and 42; 
proportion of patients with parasitaemia on days 1, 2, 
and 3; rate of gametocyte carriage; and proportion of 
patients with fever on days 1, 2, and 3. Pharmacokinetic 
analyses were also included as a secondary endpoint and 
will be presented elsewhere. The safety endpoints were 
proportion and severity of adverse events, time of any 
vomiting relative to and within 60 min of treatment, and 
proportions of serious adverse events and adverse events 
that led to treatment discontinuation.
Statistical analysis
The main features of the statistical methods were 
described in the protocol and detailed in the statistical 
analysis plan. The ﬁ nal version of the statistical analysis 
plan was signed before database lock and any analyses of 
results. The statistical analyses were done independently 
(Venn Life Sciences, Paris, France). The primary analysis 
tested the non-inferiority of artesunate–meﬂ oquine over 
artemether–lumefantrine, using the per-protocol analysis 
of PCR-adjusted ACPR at day 63. The per-protocol 
population consisted of all patients without a major 
Intention to treat Per protocol
Artesunate–meﬂ oquine (n=472) Artemether–lumefantrine (n=472) Artesunate–meﬂ oquine (n=407) Artemether–lumefantrine (n=407)
Age (months), mean (range; SD) 30·35 (6·0–59·8; 14·76) 29·72 (6·0–59·7; 14·33) 30·49 (6·0–59·8; 14·78); 29·93 (6·0–59·7; 14·36)
Sex
Female 242 (51%) 218 (46%) 209 (51%) 188 (46%)
Male 230 (49%) 254 (54%) 198 (49%) 219 (54%)
Ratio (male:female) 0·95 1·16 0·95 1·16
Plasmodium falciparum parasite count (per μL)
Mean (SD) 66 205·5 (55 126·32) 66 078·92 (53 420·44) 65 299·39 (53 532·58) 66 520·83 (54 718·61)
Median (range) 47 368 (237–268 787) 50 925 (1935–199 928) 48 187·0 (2034·0–268 787·0) 49 892·0 (1935·0–199 928·0)
Axillary temperature (°C)
Mean (SD) 38·62 (0·82) 38·61 (0·82) 38·65 (0·82) 38·62 (0·82)
Median (range) 38·5 (37·5–40·7) 38·5 (37·5–41·0) 38·5 (37·5–40·7) 38·5 (37·5–41·0)
Gametocytaemia 22 (5%) 25 (5%) 21 (5%) 22 (5%)
Concentration (per μL), range 0–1380 0–384 0·00–280·0 0·00–370·0
Missing samples 1 3 1 3
Haemoglobin (g/L) 95·1 (17·2) 94·7 (19·0) 94·9 (17·2) 94·7 (19·1)
Missing samples 0 1 0 0
Neutrophils (× 10³ per μL) 5·15 (2·85) 5·18 (2·76) 5·16 (2·87) 5·13 (2·70)
Missing samples 12 15 10 11
Platelets (× 10³ per μL) 176·25 (102·78) 174·30 (102·77) 179·18 (105·00) 174·95 (104·05)
Missing samples 0 1 0 0
Leucocytes (× 10³ per μL) 9·70 (3·90) 9·80 (3·93) 9·76 (4·00) 9·68 (3·82)
Headache 59 (13%) 65 (14%) 52 (13%) 58 (14%)
Missing samples 1 1 0 1
Vomiting 71 (15%) 46 (10%) 63 (15%) 37 (9%)
Missing samples 1 0 0 0
Gastrointestinal disorders 2 (<1%) 3 (1%) 1 (<1%) 3 (1%)
Loss of appetite or anorexia 139 (30%) 146 (31%) 122 (30%) 115 (28%)
Missing samples 1 0 0 0
Data are n (%), mean (SD), or median (range), unless otherwise indicated. For some parameters, patient samples were missing; number of missing samples is only indicated for parameters for which samples 
were missing.  
Table 1: Baseline characteristics of the two treatment groups for intention-to-treat and per-protocol populations
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protocol deviation, who were fully treatment compliant 
(deﬁ ned as ≥80% and <120% intake of study drug), who 
had a primary endpoint at day 63, and who did not 
withdraw from study treatment (except for those who 
withdrew because of adverse events or an absence of 
eﬃ  cacy). Patients who withdrew because of adverse 
events were initially excluded from the per-protocol 
population according to the protocol, but, during the 
development of the statistical analysis plan, it was 
decided they be included in the per-protocol population 
and imputed as failures because withdrawals due to 
adverse events could potentially be linked to treatment. 
Non-inferiority was shown if the lower limit of the 
95% CI for the diﬀ erence between groups was greater 
than –5%. A further analysis of PCR-adjusted ACPR at 
day 63 (with the same method as for the per-protocol 
analysis) was done in the intention-to-treat population, 
which consisted of all randomly allocated patients who 
received at least one dose of study drug. No adjustment 
on any baseline covariate was performed. For the 
intention-to-treat analysis, we imputed missing primary 
endpoint data. We did an additional Kaplan-Meier 
analysis (log-rank test) of the rate of PCR-adjusted ACPR 
using a modiﬁ ed intention-to-treat population deﬁ ned as 
all intention-to-treat patients except for those with 
undetermined or missing PCR results. This analysis, not 
planned in the protocol, was added to the statistical 
analysis plan to follow the 2009 WHO guidelines.17 A 
sample size of 399 patients per treatment was calculated 
to be required for 90% power with 2·5% signiﬁ cance for 
the one-sided comparison of rate of treated patients 
attaining a PCR-adjusted ACPR at day 63; this calculation 
was based on the assumptions that 95% of patients 
treated with artemether–lumefantrine would achieve the 
primary endpoint, an expected diﬀ erence of 0%, and a 
clinically relevant non-inferiority margin of 5%. To allow 
for an expected loss to follow-up of 15%, target 
recruitment was 470 patients in each treatment group.
Wilcoxon-Mann-Whitney or Kruskal-Wallis tests were 
used for comparison of non-normally distributed 
continuous variables. The diﬀ erences between treatments 
in the parasite reduction ratios, measured at intervals 
during the ﬁ rst 3 days after the start of treatment, were 
analysed using a linear mixed eﬀ ects model, with parasite 
reduction ratio as the dependent variable and treatment 
group, baseline parasite count, and site as independent 
variables, and the time interval as random eﬀ ect 
(the parasite count was derived from thick smear counts; 
counts of 0 were assigned a value of 1 for the analysis). 
Parasite clearance parameters were calculated using the 
Worldwide Antimalarial Resistance Network (WWARN) 
parasite clearance estimator.18
The safety analyses included all randomised patients 
who took at least one dose of study drug and had at least 
one exploitable safety measure. Analyses were done with 
SAS version 9.2. This trial is registered with ISRCTN, 
number ISRCTN17472707, and the Pan African Clinical 
Trials Registry, number PACTR201202000278282.
Role of funding source
DNDi was responsible for the study design, collection of 
data, interpretation of results, and reviewing the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
2339 children were screened, of whom 945 were recruited 
and entered randomisation, with 944 receiving either of 
the study treatments (ﬁ gure 1). The most common 
reason for non-inclusion was low or absent parasitaemia. 
The treatment groups had similar baseline demographic 
and clinical characteristics (table 1); however, vomiting at 
baseline was more frequent in the artesunate–meﬂ oquine 
group (15% of children) than in the artemether–
lumefantrine group (10%). The ﬁ rst patient entered the 
trial on Dec 13, 2010, and the last patient completed the 
trial on Oct 1, 2013.
The analysis populations are listed and deﬁ ned in 
the appendix. In the per-protocol population, the 
PCR-corrected ACPR rate at day 63 was 370 (90·9%) of 
407 patients in the artesunate–meﬂ oquine group 
compared with 365 (89·7%) of 407 in the artemether–
lumefantrine group (treatment diﬀ erence 1·23%, 95% CI 
Artesunate–meﬂ oquine 
(per-protocol n=407; 
intention-to-treat n=472)
Artemether–lumefantrine 
(per-protocol n=407; 
intention-to-treat n=472)
Diﬀ erence, %
(95% CI)
Day 63
Per-protocol population
PCR-corrected ACPR 370 (90·9%) 365 (89·7%) 1·23 (–2·84 to 5·29)
Non-PCR-corrected ACPR 201 (49·4%) 200 (49·1%) 0·25 (–6·62 to 7·11)
Intention-to-treat population
PCR-corrected ACPR 376 (79·7%) 367 (77·8%) 1·91 (–3·31 to 7·13)
Non-PCR-corrected ACPR 203 (43·0%) 201 (42·6%) 0·42 (–5·89 to 6·74)
Day 42
Per-protocol population
PCR-corrected ACPR 381 (93·6%) 375 (92·1%) 1·47 (–2·06 to 5·01)
Non-PCR-corrected ACPR 253 (62·2%) 234 (57·5%) 4·67 (–2·06 to 11·4)
Intention-to-treat population
PCR-corrected ACPR 397 (84·1%) 384 (81·4%) 2·75 (–2·06 to 7·57)
Non-PCR-corrected ACPR 266 (56·4%) 243 (51·5%) 4·87 (–1·48 to 11·22)
Day 28
Per-protocol population
PCR-corrected ACPR 397 (97·5%) 385 (94·6%) 2·95 (0·29 to 5·61)
Non-PCR-corrected ACPR 331 (81·3%) 289 (71·0%) 10·32 (4·51 to 16·13)
Intention-to-treat population
PCR-corrected ACPR 422 (89·4%) 402 (85·2%) 4·24 (–0·00 to 8·48)
Non-PCR-corrected ACPR 355 (75·2%) 306 (64·8%) 10·38 (4·57 to 16·19)
Data are n (%), unless otherwise indicated. The non-inferiority of artesunate–meﬂ oquine over artemether–lumefantrine 
is shown when the lower limit of the 95% CI for the diﬀ erence between groups is greater than –5%.
Table 2: Rates of adequate clinical and parasitological response (ACPR)
See Online for appendix
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–2·84% to 5·29%; table 2), showing non-inferiority 
of artesunate–meﬂ oquine for the primary endpoint. 
Findings were similar when the intention-to-treat 
population was used in the analysis (diﬀ erence in 
PCR-corrected ACPR rate at day 63 of 1·91%, 95% CI 
–3·31% to 7·13%; table 2).
Additional by-site analysis prespeciﬁ ed in the 
statistical analysis plan showed that the PCR-corrected 
ACPR rates at day 63 (per-protocol population) were 
similar between groups at each of the individual trial 
centres (Kilosa, Tanzania: 15 [88·2%] of 17 patients in 
the artesunate–meﬂ oquine group vs 17 [89·5%] of 
19 patients in the artemether–lumefantrine group; 
Bagamoyo, Tanzania: 21 [100%] of 21 vs 18 [85·7%] of 21; 
Korogwe, Tanzania: 41 [100%] of 41 vs 50 [98·0%] of 51; 
Kisumu, Kenya: 121 [81·8%] of 148 vs 108 [79·4%] of 
136; Balonghin, Burkina Faso: 120 [97·6%] of 123 vs 
117 [95·9%] of 122; Banfora, Burkina Faso: 52 [91·2%] 
of 57 vs 55 [94·8%] of 58). The small sample sizes 
prevented meaningful statistical analysis.
The non-PCR-corrected ACPR rates at day 63 were very 
similar in the two treatment groups, in both the 
per-protocol and intention-to-treat analyses (table 2), 
and were non-signiﬁ cant in non-inferiority analysis 
(insuﬃ  cient power for statistical analysis). Non-inferiority 
of artesunate–meﬂ oquine to artemether–lumefantrine 
was shown for the PCR-corrected ACPR rates at days 28 
and 42 in both the per-protocol and intention-to-treat 
analyses (table 2).
The Kaplan-Meier analysis (see appendix; modiﬁ ed 
intention-to-treat population) showed no diﬀ erence in 
eﬃ  cacy between artesunate–meﬂ oquine and artemether–
lumefantrine (p=0·8153, log-rank test), with higher 
PCR-corrected ACPR rates for both treatments than in 
the per-protocol non-inferiority analysis. There were 
13 ACPR failures with artesunate–meﬂ oquine and 
16 with artemether–lumefantrine in the per-protocol 
non-inferiority analysis, and 17 and 18, respectively, in 
the Kaplan-Meier modiﬁ ed intention-to-treat analysis 
(appendix).
A similar number of patients in the artesunate–
meﬂ oquine (n=204) and artemether–lumefantrine (n=202) 
groups completed the 63-day study period (table 3). There 
were two early treatment failures, both in the artesunate–
meﬂ oquine group (0·4% of 472 patients); both patients 
developed danger signs of severe malaria with parasitaemia 
on the ﬁ rst day of treatment and switched treatment to 
intravenous quinine. There were similar numbers of late 
treatment failures in the artesunate–meﬂ oquine (n=214) 
and artemether–lumefantrine (n=211) groups; these were 
similarly divided, within treatment groups, between late 
clinical and late parasitological failures (table 3). The PCR 
analysis showed 15 cases of recrudescence in the 
artesunate–meﬂ oquine group and 17 cases in the 
artemether–lumefantrine group, in the per-protocol 
population (15 vs 18 in the intention-to-treat population; 
appendix). Thus, most recurrences were re-infections, with 
similar proportions in the two treatment groups in both 
per-protocol (169 [43·8%] of 386 patients in the artesunate–
meﬂ oquine group vs 165 [43·0%] of 384 in the artemether–
lumefantrine group) and intention-to treat (173 [38·8%] of 
446 vs 166 [37·4%] of 444) populations (denominators 
exclude patients with missing PCR analysis; appendix). 
Comparison of cumulative weekly rates of re-infections, 
recrudescences, and indeterminate recurrences during 
follow-up in the per-protocol population shows a delay of 
about 7 days, up to day 49, with artesunate–meﬂ oquine 
relative to artemether–lumefantrine (ﬁ gure 2).
24 h after the start of treatment, 266 (65·4%) of 
407 patients in the artesunate–meﬂ oquine group and 
297 (73·2%) of 406 in the artemether–lumefantrine 
group had parasitaemia (per-protocol population; 
p=0·0160, Pearson χ² test). At 48 h, the proportions were 
20 (6·3%) of 320 in the artemether–lumefantrine group 
and 24 (7·2%) of 332 in the artemether–lumefantrine 
group. At 72 h, no patients in either group had 
parasitaemia (none of 324 in the artesunate–meﬂ oquine 
group and none of 329 in the artemether–lumefantrine 
group; per-protocol population). In both the per-protocol 
and intention-to-treat analyses, the mean time to 
Artesunate–
meﬂ oquine 
(n=472)
Artemether–
lumefantrine 
(n=472)
Completed study 204 (43·2%) 202 (42·8%)
Withdrawal from study 268 (56·8%) 270 (57·2%)
Reasons for withdrawal*
Early treatment failure
Parasitaemia with sign/danger 
of severe malaria on 
days 0, 1, or 2
2 (0·7%) 0
Higher parasitaemia on day 2 
than day 0
0 0
Parasitaemia on day 3 with 
axillary temperature of 
≥37·5°C
0 0
Parasitaemia count on day 3 
≥25% than on day 0
0 0
Late treatment failure
Late clinical failure 61 (22·8%) 69 (25·6%)
Late parasitological failure 153 (57·1%) 142 (52·6%)
Adverse event 8 (3·0%) 4 (1·5%)
Serious adverse event 0 2 (0·7%)
Parent or guardian’s decision 12 (4·5%) 21 (7·8%)
Intake of other antimalarial 
drugs
2 (0·7%) 0
Intake of antibiotics with 
antimalarial activity
2 (0·7%) 2 (0·7%)
Investigator’s decision 1 (0·4%) 0
Lost to follow-up 25 (9·3%) 24 (8·9%)
Other reason 2 (0·7%) 6 (2·2%)
Data are n (%). *Percentage values indicate proportion of withdrawals.
Table 3: Study withdrawals and reasons (intention-to-treat population)
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parasite clearance did not diﬀ er between treatment 
groups (analyses exclude those with missing data). 
P falciparum gametocytes were detected (thick blood 
smears) in few patients at baseline (intention-to-treat 
population: 22 [4·7%] of 471 patients in the artesunate–
meﬂ oquine group and 25 [5·3%] of 469 in the artemether–
lumefantrine group; per-protocol population: 21 [5·2%] of 
406 vs 22 [5·4%] of 404; analyses exclude those with 
missing data). At 48 h and 72 h (approximately 20% with 
missing data), the gametocyte carriage rates were 
14 (4·4%) of 318 patients and seven (2·2%) of 319 patients 
in the artesunate–meﬂ oquine group and 17 (5·2%) of 
329 patients and 12 (3·8%) of 317 patients in the 
artemether–lumefantrine group, respectively (per-protocol 
population). No patient at days 28, 42, and 63 had 
detectable gametocytes.
Between 24 h and 48 h after the start of treatment, 
axillary temperatures of more than 37·5°C were 
signiﬁ cantly less frequent in patients in the artesunate–
meﬂ oquine group (45 [11·1%] of 406) than in patients in 
the artemether–lumefantrine group (85 [20·9%] of 407; 
per-protocol population; p=0·0002; Fisher’s exact test). 
After 48 h, the proportions declined and were similar in 
both treatment groups. The mean time to attain an 
axillary temperature of 37·5°C or lower was slightly 
shorter with artesunate–meﬂ oquine (6·5 h) than with 
artemether–lumefantrine (7·5 h). These ﬁ ndings were 
unaﬀ ected by the number of patients taking para-
cetamol, which was similar between groups (between 
24 h and 48 h: 302 patients in the artesunate–meﬂ oquine 
group vs 300 in the artemether–lumefantrine group). 21 
(4·8%) of 436 patients in the artesunate–meﬂ oquine 
group had fever 72 h after the start of treatment versus 
24 (5·4%) of 444 in the artemether–lumefantrine group.
Table 4 lists adverse events that occurred in more than 
5% of patients. The frequencies of adverse events were 
similar in the two treatment groups and were similarly 
high for anaemia, cough, upper respiratory tract 
infection, vomiting (early and late), bronchitis, and 
diarrhoea. In the second follow-up period, fewer adverse 
events had an incidence of more than 5% of patients and, 
notably, less than 5% of patients in each treatment group 
reported anaemia or vomiting.
Artesunate–
meﬂ oquine
Artemether–
lumefantrine
First 63-day follow-up
Number of patients 468 465
Blood and lymphatic system disorders
Anaemia 130 (27·8%) 104 (22·4%)
Gastrointestinal disorders
Diarrhoea 57 (12·2%) 43 (9·2%)
Vomiting 69 (14·7%) 77 (16·6%)
General disorders and administration site conditions
Pyrexia 34 (7·3%) 22 (4·7%)
Infections and infestations
Bronchitis 56 (12·0%) 52 (11·2%)
Gastroenteritis 27 (5·8%) 19 (4·1%)
Pneumonia 24 (5·1%) 21 (4·5%)
Rhinitis 41 (8·8%) 48 (10·3%)
Tinea capitis 38 (8·1%) 19 (4·1%)
Upper respiratory tract infection 93 (19·9%) 87 (18·7%)
Metabolism and nutrition disorders
Decreased appetite 34 (7·3%) 23 (4·9%)
Respiratory, thoracic, and mediastinal disorders
Cough 98 (20·9%) 92 (19·8%)
Rhinorrhoea 40 (8·5%) 30 (6·5%)
Skin and subcutaneous tissue disorders
Rash 32 (6·8%) 22 (4·7%)
Second 63-day follow-up after treatment with the alternative test 
treatment
Number of patients 192 171
General disorders and administration site conditions
Pyrexia 10 (5·2%) 4 (2·3%)
Infections and infestations
Bronchitis 6 (3·1%) 9 (5·3%)
Rhinitis 5 (2·6%) 12 (7·0%)
Upper respiratory tract infection 19 (9·9%) 16 (9·4%)
Respiratory, thoracic, and mediastinal disorders
Cough 18 (9·4%) 15 (8·8%)
Second 63-day follow-up after treatment with antimalarial other 
than artesunate–meﬂ oquine or artemether–lumefantrine
Number of patients 33 48
Blood and lymphatic system disorders
Anaemia 2 (6·1%) 1 (2·1%)
Gastrointestinal disorders
Diarrhoea 1 (3·0%) 3 (6·3%)
Infections and infestations
Malaria 4 (12·1%) 3 (6·3%)
Data are n (%). Data show adverse events occurring in more than 5% of patients 
during the ﬁ rst follow-up (up to day 63 or until the day before start of rescue 
treatment); the second follow-up of patients receiving, as rescue treatment, the 
alternative investigated drug; and the second follow-up of patients receiving, as 
rescue treatment, an antimalarial drug other than the alternative investigated drug. 
Table 4: Adverse events occurring in more than 5% of patients, by 
study period
Figure 2: Cumulative number of recurrences at weekly intervals during follow-up 
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During the ﬁ rst follow-up period, nervous system 
disorders were infrequent overall but more frequent in 
the artesunate–meﬂ oquine group than in the artemether–
lumefantrine group (ten [2·1%] of 468 patients vs ﬁ ve 
[1·1%] of 465). Six patients in the artesunate–meﬂ oquine 
group had convulsions or febrile convulsions and 
two patients in the artemether–lumefantrine group had 
convulsions, with two patients in each treatment group 
having such events during the 3 days of treatment. The 
frequencies of the other CNS adverse events, headache 
and lethargy, were similar between groups: three (0·6%) 
patients in the artesunate–meﬂ oquine group and 
two (0·4%) patients in the artemether–lumefantrine 
group had headache; one (0·2%) patient in each group 
had lethargy. However, none of the CNS adverse events 
were deemed related to study treatment by the 
investigator or led to study treatment discontinuation or 
were serious adverse events. No psychiatric disorders 
were reported in any patient.
The proportion of patients presenting with early 
vomiting was similar between groups (71 [15·3%] of 
463 patients in the artesunate–meﬂ oquine group vs 
79 [16·8%] of 471 in the artemether–lumefantrine group 
in any of the three dosing days), when considering the 
two artemether–lumefantrine daily doses together 
(appendix). The overall proportion per day decreased 
from 10·5% (98 of 930 patients) to 3·5% (32 of 
903 patients) over the 3 days and most (>90%) children 
who vomited within 1 h of treatment did not vomit 
following treatment readministration.
The frequency and descriptions of reported adverse 
events are further summarised in the appendix. During 
the ﬁ rst 63-day follow-up period, similar proportions of 
patients in the artesunate–meﬂ oquine and artemether–
lumefantrine groups had at least one adverse event; a 
non-signiﬁ cant greater proportion of patients in the 
artemether–lumefantrine group had an adverse event 
during treatment (165 [35·5%] of 465 patients in the 
artesunate–meﬂ oquine group vs 138 [29·5%] of 468 in the 
artemether–lumefantrine group; p=0·0590). For both 
treatments, about 10% of patients (46 of 468 in the 
artesunate–meﬂ oquine group vs 49 of 465 in the 
artemether–lumefantrine group) had an adverse event that 
could be at least possibly related to treatment (according to 
the investigator). Treatment was discontinued because of 
an adverse event in ten (2·1%) patients in the artesunate–
meﬂ oquine group and in four (0·9%) patients in the 
artemether–lumefantrine group (p=0·1763), with vomiting 
the reason for treatment discontinuation in eight and four 
patients, respectively. A similar number of serious adverse 
events (mostly anaemia or infection) occurred with 
artesunate–meﬂ oquine (n=16) as with artemether–
lumefantrine (n=14), with one life-threatening adverse 
event and no fatalities. The life-threatening adverse event 
was anaemia, reported on day 1 of artesunate–meﬂ oquine 
treatment, and led to early treatment failure caused by 
severe malaria and suspected sepsis, and recorded as 
possibly related to treatment. Overall, 18 (1·9%) of 
933 patients had at least one serious adverse event, mostly 
infection (in seven patients in the artesunate–meﬂ oquine 
group and ﬁ ve in the artemether–lumefantrine group; 
pneumonia being most common with three cases in each 
group) or anaemia (two vs four patients). Of these patients, 
ﬁ ve in the artesunate–meﬂ oquine group and two in the 
artemether–lumefantrine group had the serious adverse 
event during treatment.
During the second 63-day follow-up period with 
artesunate–meﬂ oquine or artemether–lumefantrine as 
rescue treatment, the frequency of adverse events was 
generally lower than in the ﬁ rst 63-day follow-up period 
and proportions were similar between the two treatment 
groups (appendix), possibly inﬂ uenced by the lower 
frequency of visits during the second follow-up period. 
During this follow-up, the relation of adverse events to 
rescue treatment was only recorded in the centres in 
Burkina Faso, where no patient had an adverse event 
that was at least possibly related to treatment. The 
frequency of serious adverse events was also lower in the 
second 63-day follow-up period than in the ﬁ rst 63-day 
follow-up. Five patients treated with artemether–
lumefantrine as rescue treatment and two patients 
treated with artesunate–meﬂ oquine as rescue treatment 
had at least one serious adverse event, which were all 
infections. Four and two patients in the respective 
groups of patients receiving rescue treatment other than 
artesunate–meﬂ oquine or artemether–lumefantrine had 
at least one serious adverse event (either anaemia or 
infection).
Discussion
Our study provides important ﬁ ndings on the use of 
artesunate–meﬂ oquine in the treatment of children 
younger than 5 years with uncomplicated P falciparum 
infection in Africa. It included a 63-day follow-up and an 
extensive safety assessment, and provides much-needed 
additional data on the use of artesunate–meﬂ oquine in 
young African children.19 To our knowledge, this is the 
ﬁ rst trial of artesunate–meﬂ oquine with a design 
compliant with current WHO guidelines in this 
especially vulnerable population.2
The primary outcome, the rate of PCR-corrected ACPR 
at day 63 in the per-protocol population, was very 
similar in the artesunate–meﬂ oquine and artemether–
lumefantrine groups, with a percentage diﬀ erence that 
had a lower bound of the 95% CI (–2·84%) greater than 
–5%. Thus, the criterion for the non-inferiority of 
artesunate–meﬂ oquine to artemether–lumefantrine was 
met in young African children. The cure rates were 
similar to, although a little below, published rates for the 
two ACTs in mixed-aged populations in non-African 
countries, including trials with the ﬁ xed-dose artesunate–
meﬂ oquine tablet.9,14 We found no published data on 
63-day cure rates for artesunate–meﬂ oquine and 
artemether–lumefantrine in young children. All our 
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patients were admitted to hospital for treatment and 
compliance was 100%, or just less, at all sites during the 
3 days of treatment.
Previously, in studies in populations of mixed age in 
Senegal,20 Nigeria,21 Mali,22 and Kenya,23 artesunate–
meﬂ oquine was reported to be eﬀ ective and well tolerated. 
These trials each used a follow-up of just 28 days, which 
might be too short to fully assess accurate cure rates and 
safety of artesunate–meﬂ oquine because of meﬂ oquine’s 
slow elimination. The low deployment of artesunate–
meﬂ oquine in Africa might result from the early vomiting 
and neuropsychiatric eﬀ ects reported with meﬂ oquine 
monotherapy,24 and also from the absence of a ﬁ xed-dose 
paediatric formulation. In this study we tested a ﬁ xed-dose 
artesunate–meﬂ oquine tablet, designed to optimise the 
compliance of a 3-day combination treatment and to 
improve the tolerability of meﬂ oquine by dividing the dose 
into three equal daily doses. We found that the ﬁ xed-dose 
artesunate–meﬂ oquine tablet has a good safety proﬁ le that 
is similar to that of artemether–lumefantrine, with a low 
risk of repeated early vomiting during the treatment period 
and a low incidence of neuropsychiatric adverse events, 
which were deemed unrelated to study treatment.
The parasite clearance rate was rapid with both ACTs, 
with most children showing complete parasite clearance 
within 2 days. The parasite reduction ratios for both 
artesunate–meﬂ oquine and artemether–lumefantrine 
are high compared with published values.25 Artesunate–
meﬂ oquine was marginally superior to artemether–
lumefantrine in the rapidity of parasite clearance and the 
slightly more rapid decline in fever. Although these 
diﬀ erences might be chance ﬁ ndings, the high parasite 
reduction ratios serve to strengthen our evidence of the 
eﬃ  cacy of artesunate–meﬂ oquine in African children 
by comparison with artemether–lumefantrine. Rapid 
parasite clearance and fever reduction are essential to 
ensure compliance with antimalarial treatment.
There were only two early treatment failures overall. By 
day 63, the rates of late treatment failure were similar for 
artesunate–meﬂ oquine and artemether–lumefantrine, 
and mostly caused by re-infection. We detected that, up to 
day 49, the cumulative rates of recrudescence and of re-
infection were each delayed by about 7 days with 
artesunate–meﬂ oquine relative to those with artemether–
lumefantrine. A similar ﬁ nding was reported by Sagara 
and colleagues22 in their trial of artesunate–meﬂ oquine 
versus artemether–lumefantrine in Mali.22 These ﬁ ndings 
suggest that artesunate–meﬂ oquine provides longer 
protection against malaria than artemether–lumefantrine, 
possibly because of the longer half-life of meﬂ oquine 
compared with lumefantrine, with reported median 
terminal clearance half-lives of about 20 days26 and 
5 days,27 respectively. By day 63, the comparative eﬃ  cacy 
is unaﬀ ected by the diﬀ erent clearance rates.
We found the safety proﬁ les of artesunate–meﬂ oquine 
and artemether–lumefantrine to be similar, with low 
frequencies of nervous system disorders and no 
psychiatric disorders. Our investigators were instructed 
to look for possible neuropsychiatric disorders, but no 
active neurological testing was done. Relevant 
neuropsychiatric adverse events are diﬃ  cult to identify 
in young children and are consequently under-reported. 
Another study of artesunate–meﬂ oquine (ﬁ xed dose of 
50 mg artesunate and 125 mg meﬂ oquine per day for 
3 days) in 213 young children in Africa,28 with a 63-day 
follow-up, actively tested for neuropsychiatric eﬀ ects 
(using standard infant neurological tests) and reported 
mild-to-moderate, spontaneously resolving neuro-
psychiatric adverse events, with sleeping disorders being 
the most common (2·3% of patients). Notably, because 
of the risk of serious psychiatric side-eﬀ ects, the latest 
WHO antimalarial treatment guideline3 recommends an 
interval of 60 days between consecutive periods of 
meﬂ oquine treatment.
In children younger than 5 years, meﬂ oquine has been 
associated with early vomiting causing impaired 
absorption,29 but studies, including in young children, 
show that the incidence of early vomiting is substantially 
reduced by splitting the meﬂ oquine dose across 
successive days and by coadministration with artesunate. 
In a mixed-aged population, early vomiting was reported 
in only 3% of patients treated with ﬁ xed-dose artesunate–
meﬂ oquine.13 Dividing the meﬂ oquine dose across 2 or 
3 days does not aﬀ ect eﬃ  cacy because of its slow 
clearance. In our study population, about 10% had early 
vomiting but less than 10% of these patients vomited 
after readministration. Lower rates were measured in 
mixed-aged populations in large trials in Brazil8 and in 
Burma,9 with the same ﬁ xed-dose artesunate–meﬂ oquine 
tablet that we tested here.
Our study has limitations. It is an open-labelled study 
and was not powered for safety. However, to our knowledge, 
it is the largest randomised controlled trial providing 
eﬃ  cacy and safety data for artesunate–meﬂ oquine in 
children in Africa. We conclude that ﬁ xed-dose artesunate–
meﬂ oquine is safe and eﬀ ective in treating young African 
children with uncomplicated malaria. This combination is 
shown to be as eﬀ ective as artemether–lumefantrine, 
which is recognised as a safe and eﬃ  cacious antimalarial 
drug in children.19 Our data are derived from a large trial, 
optimally designed for testing an ACT, such as 
artesunate–meﬂ oquine, with a slowly cleared active 
component. We believe our results support the deployment 
of ﬁ xed-dose artesunate–meﬂ oquine in young children in 
Africa. Our ﬁ ndings should have important implications 
for health policy in sub-Saharan Africa.
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